Status:
COMPLETED
Erythropoietin in Hemolytic Uremic Syndrome
Lead Sponsor:
Hospital General de Niños Pedro de Elizalde
Conditions:
Hemolytic-Uremic Syndrome
Anemia
Eligibility:
All Genders
1-18 years
Phase:
PHASE4
Brief Summary
This study will evaluate the impact of early administration of erythropoietin in the number of red blood cell transfusions in children with Shiga toxin-producing Escherichia coli hemolytic uremic synd...
Detailed Description
Introduction: Anemia in STEC-HUS is treated with red blood cell (RBC) transfusions. It can causes hypervolemia, hyperkalemia, exacerbate the thrombotic state of the disease, transmit infectious agent...
Eligibility Criteria
Inclusion
- Post diarrheal HUS: Prodrome of enteritis followed by microangiopathic hemolytic anemia, thrombocytopenia and signs of renal damage (increased plasma creatinine, proteinuria, and / or hematuria). Proven STEC infection wiil not be required to enter into the study.
Exclusion
- Atypical HUS
- HUS associated with systemic diseases (pneumococcal infection, HIV, Systemic lupus erythematosus) or drugs
- Anemia or known kidney disease
- Previously transfused or treated with erythropoietin
- Contraindications to erythropoietin
Key Trial Info
Start Date :
January 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT03776851
Start Date
January 1 2019
End Date
December 30 2020
Last Update
January 13 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
HGNPE
CABA, Argentina, 1417